Chemed Corp. (CHE) Given News Sentiment Score of 0.10
Press coverage about Chemed Corp. (NYSE:CHE) has trended somewhat positive this week, Accern Sentiment reports. Accern identifies negative and positive media coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Chemed Corp. earned a coverage optimism score of 0.10 on Accern’s scale. Accern also gave media headlines about the company an impact score of 46.3213956367032 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
These are some of the news stories that may have impacted Accern Sentiment Analysis’s scoring:
- Why Should Investors Add Amedisys (AMED) to Their Portfolio? (finance.yahoo.com)
- Here's Why You Should Add Chemed (CHE) to Your Portfolio (finance.yahoo.com)
- Noteworthy Monday Option Activity: CHE, SBGI, NXST (stockoptionschannel.com)
- Chemed Getting Closer To Key Technical Measure (finance.yahoo.com)
- Chemed Corp. (CHE) Stock Rating Upgraded by Zacks Investment Research (americanbankingnews.com)
Several research analysts have recently commented on CHE shares. BidaskClub lowered Chemed Corp. from a “strong-buy” rating to a “buy” rating in a report on Thursday, June 22nd. Oppenheimer Holdings, Inc. boosted their price objective on Chemed Corp. from $200.00 to $220.00 and gave the stock an “outperform” rating in a report on Thursday, July 27th. Zacks Investment Research raised Chemed Corp. from a “hold” rating to a “buy” rating and set a $226.00 price objective for the company in a report on Friday, July 28th. Royal Bank Of Canada reissued a “hold” rating and set a $208.00 price objective on shares of Chemed Corp. in a report on Wednesday, July 5th. Finally, TheStreet lowered Chemed Corp. from a “b+” rating to a “c+” rating in a report on Tuesday, July 25th. Two research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Chemed Corp. presently has an average rating of “Buy” and an average price target of $215.00.
Shares of Chemed Corp. (CHE) opened at 190.74 on Friday. The firm has a 50-day moving average price of $193.25 and a 200 day moving average price of $196.09. The stock has a market cap of $3.05 billion, a price-to-earnings ratio of 47.32 and a beta of 1.14. Chemed Corp. has a 52 week low of $132.92 and a 52 week high of $216.01.
Chemed Corp. (NYSE:CHE) last released its quarterly earnings data on Tuesday, July 25th. The company reported $2.15 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.89 by $0.26. Chemed Corp. had a return on equity of 26.18% and a net margin of 4.16%. The business had revenue of $415.06 million for the quarter, compared to the consensus estimate of $407.56 million. During the same quarter in the previous year, the company posted $1.80 EPS. The company’s revenue was up 6.3% compared to the same quarter last year. On average, analysts forecast that Chemed Corp. will post $8.21 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which was paid on Friday, September 1st. Shareholders of record on Monday, August 14th were paid a $0.28 dividend. This is an increase from Chemed Corp.’s previous quarterly dividend of $0.26. The ex-dividend date of this dividend was Thursday, August 10th. This represents a $1.12 dividend on an annualized basis and a yield of 0.59%. Chemed Corp.’s payout ratio is presently 28.07%.
In other Chemed Corp. news, insider Spencer S. Lee sold 1,000 shares of Chemed Corp. stock in a transaction that occurred on Friday, September 1st. The stock was sold at an average price of $197.46, for a total value of $197,460.00. Following the sale, the insider now owns 37,809 shares of the company’s stock, valued at approximately $7,465,765.14. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Kevin J. Mcnamara sold 15,000 shares of Chemed Corp. stock in a transaction that occurred on Friday, July 28th. The stock was sold at an average price of $201.16, for a total value of $3,017,400.00. Following the completion of the sale, the insider now directly owns 173,801 shares in the company, valued at approximately $34,961,809.16. The disclosure for this sale can be found here. Insiders own 5.32% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This piece of content was posted by Daily Political and is owned by of Daily Political. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark laws. The legal version of this piece of content can be read at https://www.dailypolitical.com/2017/09/22/chemed-corp-che-given-news-sentiment-score-of-0-10.html.
Chemed Corp. Company Profile
Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.
Receive News & Ratings for Chemed Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed Corp. and related companies with MarketBeat.com's FREE daily email newsletter.